{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:01:24Z","timestamp":1793898084661,"version":"4.8.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Semin Immunopathol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00281-019-00747-2","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T12:34:48Z","timestamp":1558096488000},"page":"491-499","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["The role of interleukin-6 in glucose homeostasis and lipid metabolism"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1947-4252","authenticated-orcid":false,"given":"Louise Lang","family":"Lehrskov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regitse H\u00f8jgaard","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,17]]},"reference":[{"key":"747_CR1","doi-asserted-by":"publisher","first-page":"5559","DOI":"10.1113\/jphysiol.2009.179515","volume":"587","author":"BK Pedersen","year":"2009","unstructured":"Pedersen BK (2009) The diseasome of physical inactivity--and the role of myokines in muscle--fat cross talk. J Physiol 587:5559\u20135568","journal-title":"J Physiol"},{"key":"747_CR2","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1152\/japplphysiol.00080.2007","volume":"103","author":"BK Pedersen","year":"2007","unstructured":"Pedersen BK, Akerstr\u00f6m TCA, Nielsen AR, Fischer CP (2007) Role of myokines in exercise and metabolism. J Appl Physiol 103:1093\u20131098","journal-title":"J Appl Physiol"},{"key":"747_CR3","doi-asserted-by":"publisher","unstructured":"Pedersen BK (2019) Physical activity and muscle\u2013brain crosstalk. Nat Rev Endocrinol. https:\/\/doi.org\/10.1038\/s41574-019-0174-x","DOI":"10.1038\/s41574-019-0174-x"},{"key":"747_CR4","first-page":"1","volume":"149","author":"D Kamimura","year":"2003","unstructured":"Kamimura D, Ishihara K, Hirano T (2003) IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 149:1\u201338","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"747_CR5","first-page":"4196","volume":"82","author":"V Mohamed-Ali","year":"1997","unstructured":"Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-\u03b1, in vivo. J Clin Endocrinol Metab 82:4196\u20134200","journal-title":"J Clin Endocrinol Metab"},{"key":"747_CR6","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1093\/intimm\/12.9.1329","volume":"12","author":"M De Rossi","year":"2000","unstructured":"De Rossi M, Bernasconi P, Baggi F, de Waal Malefyt R, Mantegazza R (2000) Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int Immunol 12:1329\u20131335","journal-title":"Int Immunol"},{"key":"747_CR7","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1152\/physrev.90100.2007","volume":"88","author":"BK Pedersen","year":"2008","unstructured":"Pedersen BK, Febbraio MA (2008) Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 88:1379\u20131406","journal-title":"Physiol Rev"},{"key":"747_CR8","doi-asserted-by":"publisher","unstructured":"Hojman P, Brolin C, N\u00f8rgaard-Christensen N, Dethlefsen C, Lauenborg B, Olsen CK, \u00c5bom MM, Krag TO, Gehl J, Pedersen BK (2019) IL-6 release from muscles during exercise is stimulated by lactate-dependent protease activity. Am J Physiol Endocrinol Metab 19. https:\/\/doi.org\/10.1152\/ajpendo.00414.2018","DOI":"10.1152\/ajpendo.00414.2018"},{"key":"747_CR9","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.7150\/ijbs.4989","volume":"8","author":"S Rose-John","year":"2012","unstructured":"Rose-John S (2012) IL-6 trans-signaling via the soluble IL-6 receptor: importance for the proinflammatory activities of IL-6. Int J Biol Sci 8:1237\u20131247","journal-title":"Int J Biol Sci"},{"key":"747_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1042\/bj3000281","volume":"300","author":"S Rose-John","year":"1994","unstructured":"Rose-John S, Heinrich PC (1994) Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 300:281\u2013290","journal-title":"Biochem J"},{"key":"747_CR11","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/0092-8674(90)90411-7","volume":"63","author":"M Hibi","year":"1990","unstructured":"Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T (1990) Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63:1149\u20131157","journal-title":"Cell"},{"key":"747_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj20030407","volume":"20","author":"PC Heinrich","year":"2003","unstructured":"Heinrich PC, Behrmann I, Haan S, Hermanns HM, Uller-newen GM (2003) Principles of IL 6 type cytokine signaling and its regulating. Biochem J 20:1\u201320","journal-title":"Biochem J"},{"key":"747_CR13","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S0006-291X(03)00792-7","volume":"305","author":"L Yang","year":"2003","unstructured":"Yang L, Wang L, Lin HK, Kan PY, Xie S, Tsai MY, Wang PH, Chen YT, Chang C (2003) Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem Biophys Res Commun 305:462\u2013469","journal-title":"Biochem Biophys Res Commun"},{"key":"747_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1126\/science.8140422","volume":"264","author":"Z Zhong","year":"1994","unstructured":"Zhong Z, Wen Z, Darnell JE (1994) Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6 author. Science. 264:95\u201398","journal-title":"Science."},{"key":"747_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1006\/clin.1997.4420","volume":"85","author":"BE Barton","year":"1997","unstructured":"Barton BE (1997) IL-6: insights into novel biological activities. Clin Immunol Immunopathol 85:16\u201320","journal-title":"Clin Immunol Immunopathol"},{"key":"747_CR16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/00000658-199204000-00009","volume":"215","author":"P Damas","year":"1992","unstructured":"Damas P et al (1992) Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 215:356\u2013362","journal-title":"Ann Surg"},{"key":"747_CR17","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1128\/MCB.10.5.2327","volume":"10","author":"TA Libermann","year":"1990","unstructured":"Libermann TA, Baltimore D (1990) Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 10:2327\u20132334","journal-title":"Mol Cell Biol"},{"key":"747_CR18","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1128\/MCB.10.7.3818","volume":"10","author":"YH Zhang","year":"1990","unstructured":"Zhang YH, Lin JX, Vilcek J (1990) Interleukin-6 induction by tumor necrosis factor and interleukin-1 in human fibroblasts involves activation of a nuclear factor binding to a kappa B-like sequence. Mol Cell Biol 10:3818\u20133823","journal-title":"Mol Cell Biol"},{"key":"747_CR19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1128\/MCB.10.2.561","volume":"10","author":"H Shimizu","year":"1990","unstructured":"Shimizu H, Mitomo K, Watanabe T, Okamoto S, Yamamoto K (1990) Involvement of a NF-kappa B-like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines. Mol Cell Biol 10:561\u2013568","journal-title":"Mol Cell Biol"},{"key":"747_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/nrrheum.2014.193","volume":"11","author":"FB Benatti","year":"2015","unstructured":"Benatti FB, Pedersen BK (2015) Exercise as an anti-inflammatory therapy for rheumatic diseases - myokine regulation. Nat Rev Rheumatol 11:86\u201397","journal-title":"Nat Rev Rheumatol"},{"key":"747_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cytogfr.2018.04.004","volume":"41","author":"N Unver","year":"2018","unstructured":"Unver N, McAllister F (2018) IL-6 family cytokines: key inflammatory mediators as biomarkers and potential therapeutic targets. Cytokine Growth Factor Rev 41:10\u201317","journal-title":"Cytokine Growth Factor Rev"},{"key":"747_CR22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3109\/07853890009011772","volume":"32","author":"T.W., D. C","year":"2000","unstructured":"T.W., D. C (2000) Function of C-reactive protein. Ann Med 32:274\u2013278","journal-title":"Ann Med"},{"key":"747_CR23","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1042\/CS20060368","volume":"112","author":"KR Wilund","year":"2007","unstructured":"Wilund KR (2007) Is the anti-inflammatory effect of regular exercise responsible for reduced cardiovascular disease? Clin Sci (Lond) 112:543\u2013555","journal-title":"Clin Sci (Lond)"},{"key":"747_CR24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1189\/jlb.0505247","volume":"78","author":"H Bruunsgaard","year":"2005","unstructured":"Bruunsgaard H (2005) Physical activity and modulation of systemic low-level inflammation. J Leukoc Biol 78:819\u2013835","journal-title":"J Leukoc Biol"},{"key":"747_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature21363","volume":"542","author":"GS Hotamisligil","year":"2017","unstructured":"Hotamisligil GS (2017) Inflammation, metaflammation and immunometabolic disorders. Nature 542:177\u2013185","journal-title":"Nature"},{"key":"747_CR26","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/nri2449","volume":"8","author":"GS Hotamisligil","year":"2008","unstructured":"Hotamisligil GS, Erbay E (2008) Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 8:923\u2013934","journal-title":"Nat Rev Immunol"},{"key":"747_CR27","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1172\/JCI45887","volume":"121","author":"K Sun","year":"2011","unstructured":"Sun K, Kusminski CM, Scherer PE (2011) Adipose tissue remodeling and obesity. J Clin Invest 121:2094\u20132101","journal-title":"J Clin Invest"},{"key":"747_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrd4275","volume":"13","author":"MY Donath","year":"2014","unstructured":"Donath MY (2014) Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov 13:465\u2013476","journal-title":"Nat Rev Drug Discov"},{"key":"747_CR29","first-page":"E433","volume":"285","author":"A Steensberg","year":"2015","unstructured":"Steensberg A, Fischer CP, Keller C, M\u00f8ller K, Pedersen BK (2015) IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Metab 285:E433\u2013E437","journal-title":"Am J Physiol Metab"},{"key":"747_CR30","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1469-7793.2001.00633.x","volume":"537","author":"A Steensberg","year":"2001","unstructured":"Steensberg A, Febbraio MA, Osada T, Schjerling P, van Hall G, Saltin B, Pedersen BK (2001) Interleukin-6 production in contracting human skeletal muscle is influenced by pre-exercise muscle glycogen content. J Physiol 537:633\u2013639","journal-title":"J Physiol"},{"key":"747_CR31","first-page":"18","volume":"7","author":"BK Pedersen","year":"2001","unstructured":"Pedersen BK, Steensberg A, Fischer C, Keller C, Ostrowski K, Schjerling P (2001) Exercise and cytokines with particular focus on muscle derived IL-6. Exerc Immunol Rev 7:18\u201331","journal-title":"Exerc Immunol Rev"},{"key":"747_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1023\/A:1026070911202","volume":"24","author":"BK Pedersen","year":"2003","unstructured":"Pedersen BK, Steensberg A, Fischer C, Keller C, Keller P, Plomgaard P, Febbraio M, Saltin B (2003) Searching for the exercise factor: is IL-6 a candidate? J Muscle Res Cell Motil 24:113\u2013119","journal-title":"J Muscle Res Cell Motil"},{"key":"747_CR33","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/j.1469-7793.1998.949bp.x","volume":"508","author":"K Ostrowski","year":"1998","unstructured":"Ostrowski K, Rohde T, Zacho M, Asp S, Pedersen B (1998) Evidence that IL-6 is produced in skeletal muscle during intense long-term muscle activity. J Physiol 508:949\u2013953","journal-title":"J Physiol"},{"key":"747_CR34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1469-7793.2000.00237.x","volume":"529","author":"A Steensberg","year":"2000","unstructured":"Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Pedersen BK (2000) Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 529:237\u2013242","journal-title":"J Physiol"},{"key":"747_CR35","first-page":"6","volume":"12","author":"C Fischer","year":"2006","unstructured":"Fischer C (2006) Interleukin-6 in acute exercise and training: what is the biological relevance. Exerc Immunol Rev 12:6\u201333","journal-title":"Exerc Immunol Rev"},{"key":"747_CR36","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1113\/jphysiol.2002.030437","volume":"546","author":"JW Helge","year":"2003","unstructured":"Helge JW, Stallknecht B, Pedersen BK, Galbo H, Kiens B, Richter EA (2003) The effect of graded exercise on IL-6 release and glucose uptake in human skeletal muscle. J Physiol 546:299\u2013305","journal-title":"J Physiol"},{"key":"747_CR37","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/cphy.c120033","volume":"3","author":"BK Pedersen","year":"2013","unstructured":"Pedersen BK (2013) Muscle as a secretory organ. Compr Physiol 3:1337\u20131362","journal-title":"Compr Physiol"},{"key":"747_CR38","unstructured":"Ullum H et al (1994) Bicycle exercise enhances plasma IL-6 but does not change IL-1\u03b1, IL-1\u03b2, IL-6, or TNF-\u03b1 pre-mRNA in BMNC. Cytokines:93\u201397"},{"key":"747_CR39","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/j.1469-7793.1998.889ba.x","volume":"513","author":"K Ostrowski","year":"1998","unstructured":"Ostrowski K, Hermann C, Bangash A, Schjerling P, Nielsen JN, Pedersen BK (1998) A trauma-like elevation of plasma cytokines in humans in response to treadmill running. J Physiol 513:889\u2013894","journal-title":"J Physiol"},{"key":"747_CR40","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1096\/fj.02-0670fje","volume":"17","author":"R Starkie","year":"2003","unstructured":"Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK (2003) Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 17:884\u2013886","journal-title":"FASEB J"},{"key":"747_CR41","doi-asserted-by":"publisher","first-page":"4966","DOI":"10.1073\/pnas.87.13.4966","volume":"87","author":"JE Gershenwald","year":"1990","unstructured":"Gershenwald JE, Fong YM, Fahey TJ, Calvano SE, Chizzonite R, Kilian PL, Lowry SF, Moldawer LL (1990) Interleukin 1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci U S A 87:4966\u20134970","journal-title":"Proc Natl Acad Sci U S A"},{"key":"747_CR42","first-page":"43","volume":"57","author":"AMW Petersen","year":"2006","unstructured":"Petersen AMW, Pedersen BK (2006) The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol 57:43\u201351","journal-title":"J Physiol Pharmacol"},{"key":"747_CR43","doi-asserted-by":"publisher","first-page":"E433","DOI":"10.1152\/ajpendo.00074.2003","volume":"285","author":"A Steensberg","year":"2003","unstructured":"Steensberg A, Fischer CP, Keller C, M\u00f8ller K, Pedersen BK (2003) IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab 285:E433\u2013E437","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"747_CR44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nm0102-75","volume":"8","author":"V Wallenius","year":"2002","unstructured":"Wallenius V, Wallenius K, Ahr\u00e9n B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75\u201379","journal-title":"Nat Med"},{"key":"747_CR45","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s00125-010-1865-y","volume":"53","author":"VB Matthews","year":"2010","unstructured":"Matthews VB, Allen TL, Risis S, Chan MHS, Henstridge DC, Watson N, Zaffino LA, Babb JR, Boon J, Meikle PJ, Jowett JB, Watt MJ, Jansson JO, Bruce CR, Febbraio MA (2010) Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 53:2431\u20132441","journal-title":"Diabetologia"},{"key":"747_CR46","doi-asserted-by":"publisher","first-page":"114","DOI":"10.2337\/diabetes.54.suppl_2.S114","volume":"54","author":"OP Kristiansen","year":"2005","unstructured":"Kristiansen OP, Mandrup-poulsen T (2005) The good, the bad, or the indifferent? Diabetes 54:114\u2013124","journal-title":"Diabetes"},{"key":"747_CR47","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrendo.2012.49","volume":"8","author":"BK Pedersen","year":"2012","unstructured":"Pedersen BK, Febbraio M a (2012) Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 8:457\u2013465","journal-title":"Nat Rev Endocrinol"},{"key":"747_CR48","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.2337\/diabetes.53.4.1060","volume":"53","author":"H-J Kim","year":"2004","unstructured":"Kim H-J, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, Kim JK (2004) Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060\u20131067","journal-title":"Diabetes"},{"key":"747_CR49","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nm1166","volume":"11","author":"D Cai","year":"2005","unstructured":"Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-\u03b2 and NF-\u03baB. Nat Med 11:183\u2013190","journal-title":"Nat Med"},{"key":"747_CR50","doi-asserted-by":"publisher","first-page":"13740","DOI":"10.1074\/jbc.M210689200","volume":"278","author":"JJ Senn","year":"2003","unstructured":"Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA (2003) Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278:13740\u201313746","journal-title":"J Biol Chem"},{"key":"747_CR51","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/dom.12170","volume":"15","author":"MJ Kraakman","year":"2013","unstructured":"Kraakman MJ, Allen TL, Whitham M, Iliades P, Kammoun HL, Estevez E, Lancaster GI, Febbraio MA (2013) Targeting gp130 to prevent inflammation and promote insulin action. Diabetes Obes Metab 15:170\u2013175","journal-title":"Diabetes Obes Metab"},{"key":"747_CR52","doi-asserted-by":"publisher","first-page":"13163","DOI":"10.1073\/pnas.0801059105","volume":"105","author":"H Ellingsgaard","year":"2008","unstructured":"Ellingsgaard H, Ehses JA, Hammar EB, van Lommel L, Quintens R, Martens G, Kerr-Conte J, Pattou F, Berney T, Pipeleers D, Halban PA, Schuit FC, Donath MY (2008) Interleukin-6 regulates pancreatic \u03b1-cell mass expansion. Proc Natl Acad Sci 105:13163\u201313168","journal-title":"Proc Natl Acad Sci"},{"key":"747_CR53","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/nm.2513","volume":"17","author":"H Ellingsgaard","year":"2011","unstructured":"Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, Eppler E, Bouzakri K, Wueest S, Muller YD, Hansen AMK, Reinecke M, Konrad D, Gassmann M, Reimann F, Halban PA, Gromada J, Drucker DJ, Gribble FM, Ehses JA, Donath MY (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17:1481\u20131489","journal-title":"Nat Med"},{"key":"747_CR54","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/j.gastro.2016.03.003","volume":"151","author":"K Timper","year":"2016","unstructured":"Timper K, Dalmas E, Dror E, R\u00fctti S, Thienel C, Sauter NS, Bouzakri K, B\u00e9dat B, Pattou F, Kerr-Conte J, B\u00f6ni-Schnetzler M, Donath MY (2016) Glucose-dependent insulinotropic peptide stimulates glucagon-like peptide 1 production by pancreatic islets via interleukin 6, produced by \u03b1 cells. Gastroenterology 151:165\u2013179","journal-title":"Gastroenterology"},{"key":"747_CR55","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/ni.2865","volume":"15","author":"J Mauer","year":"2014","unstructured":"Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD, Theurich S, Hausen AC, Schmitz J, Br\u00f6nneke HS, Estevez E, Allen TL, Mesaros A, Partridge L, Febbraio MA, Chawla A, Wunderlich FT, Br\u00fcning JC (2014) Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol 15:423\u2013430","journal-title":"Nat Immunol"},{"key":"747_CR56","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.celrep.2017.03.043","volume":"19","author":"K Timper","year":"2017","unstructured":"Timper K, Denson JL, Steculorum SM, Heilinger C, Engstr\u00f6m-Ruud L, Wunderlich CM, Rose-John S, Wunderlich FT, Br\u00fcning JC (2017) IL-6 improves energy and glucose homeostasis in obesity via enhanced central IL-6 trans-signaling. Cell Rep 19:267\u2013280","journal-title":"Cell Rep"},{"key":"747_CR57","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cmet.2010.06.011","volume":"12","author":"FT Wunderlich","year":"2010","unstructured":"Wunderlich FT, Str\u00f6hle P, K\u00f6nner AC, Gruber S, Tovar S, Br\u00f6nneke HS, Juntti-Berggren L, Li LS, van Rooijen N, Libert C, Berggren PO, Br\u00fcning JC (2010) Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab 12:237\u2013249","journal-title":"Cell Metab"},{"key":"747_CR58","first-page":"1029","volume":"47","author":"AL Carey","year":"2004","unstructured":"Carey AL, Bruce CR, Sacchetti M, Anderson MJ, Olsen DB, Saltin B, Hawley JA, Febbraio MA (2004) Interleukin-6 and tumor necrosis factor-\u03b1 are not increased in patients with type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia 47:1029\u20131037","journal-title":"Diabetologia"},{"key":"747_CR59","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cmet.2018.04.008","volume":"27","author":"L Lang Lehrskov","year":"2018","unstructured":"Lang Lehrskov L, Lyngbaek MP, Soederlund L, Legaard GE, Ehses JA, Heywood SE, Wewer Albrechtsen NJ, Holst JJ, Karstoft K, Pedersen BK, Ellingsgaard H (2018) Interleukin-6 delays gastric emptying in humans with direct effects on glycemic control. Cell Metab 27:1201\u20131211.e3","journal-title":"Cell Metab"},{"key":"747_CR60","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/324073a0","volume":"324","author":"T Hirano","year":"1986","unstructured":"Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura SI, Nakajima K, Koyama K, Iwamatsu A, Tsunasawa S, Sakiyama F, Matsui H, Takahara Y, Taniguchi T, Kishimoto T (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324:73\u201376","journal-title":"Nature"},{"key":"747_CR61","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/eji.1830180202","volume":"18","author":"J Van Snick","year":"1988","unstructured":"Van Snick J et al (1988) cDNA cloning of murine interleukin-HP1: homology with human interleukin 6. Eur J Immunol 18:193\u2013197","journal-title":"Eur J Immunol"},{"issue":"1\u20139","key":"747_CR62","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11892-015-0642-1","volume":"15","author":"SH Knudsen","year":"2015","unstructured":"Knudsen SH, Pedersen BK (2015) Targeting inflammation through a physical active lifestyle and pharmaceuticals for the treatment of type 2 diabetes. Curr Diab Rep 15(1\u20139):82","journal-title":"Curr Diab Rep"},{"key":"747_CR63","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.2337\/db05-1404","volume":"55","author":"AL Carey","year":"2006","unstructured":"Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, Febbraio MA (2006) Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55:2688\u20132697","journal-title":"Diabetes"},{"key":"747_CR64","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/icb.2015.101","volume":"94","author":"K Karstoft","year":"2016","unstructured":"Karstoft K, Pedersen BK (2016) Exercise and type 2 diabetes: focus on metabolism and inflammation. Immunol Cell Biol 94:146\u2013150","journal-title":"Immunol Cell Biol"},{"key":"747_CR65","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1210\/jcem.82.12.4422","volume":"82","author":"C Tsigos","year":"1997","unstructured":"Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP (1997) Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J.Clin.Endocrinol.Metab 82:4167\u20134170","journal-title":"J.Clin.Endocrinol.Metab"},{"key":"747_CR66","first-page":"E813","volume":"268","author":"J Stouthard","year":"1995","unstructured":"Stouthard J et al (1995) Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Phys 268:E813\u2013E819","journal-title":"Am J Phys"},{"key":"747_CR67","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1113\/jphysiol.2002.019380","volume":"543","author":"D Lyngs\u00f8","year":"2002","unstructured":"Lyngs\u00f8 D, Simonsen L, B\u00fclow J (2002) Interleukin-6 production in human subcutaneous abdominal adipose tissue: the effect of exercise. J Physiol 543:373\u2013378","journal-title":"J Physiol"},{"key":"747_CR68","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1152\/japplphysiol.00164.2004","volume":"98","author":"a MW Petersen","year":"2005","unstructured":"Petersen a MW, Pedersen BK (2005) The anti-inflammatory effect of exercise. J Appl Physiol 98:1154\u20131162","journal-title":"J Appl Physiol"},{"key":"747_CR69","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.2337\/diabetes.53.7.1643","volume":"53","author":"MA Febbraio","year":"2004","unstructured":"Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK (2004) Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 53:1643\u20131648","journal-title":"Diabetes"},{"key":"747_CR70","first-page":"E769","volume":"306","author":"NM Harder-Lauridsen","year":"2014","unstructured":"Harder-Lauridsen NM et al (2014) Effect of IL-6 on the insulin sensitivity in patients with type 2 diabetes. Am J Physiol Metab 306:E769\u2013E778","journal-title":"Am J Physiol Metab"},{"key":"747_CR71","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/nrendo.2009.62","volume":"5","author":"B F\u00e8ve","year":"2009","unstructured":"F\u00e8ve B, Bastard J-P (2009) The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 5:305\u2013311","journal-title":"Nat Rev Endocrinol"},{"key":"747_CR72","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00125-009-1580-8","volume":"53","author":"M Sadagurski","year":"2010","unstructured":"Sadagurski M, Norquay L, Farhang J, D\u2019Aquino K, Copps K, White MF (2010) Human IL6 enhances leptin action in mice. Diabetologia 53:525\u2013535","journal-title":"Diabetologia"},{"key":"747_CR73","doi-asserted-by":"publisher","unstructured":"Xu Y, Zhang Y, Ye J (2018) IL-6: a potential role in cardiac metabolic homeostasis. Int J Mol Sci 19. https:\/\/doi.org\/10.3390\/ijms19092474","DOI":"10.3390\/ijms19092474"},{"key":"747_CR74","first-page":"E155","volume":"102","author":"EW Petersen","year":"2005","unstructured":"Petersen EW et al (2005) Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Circulation 102:E155\u2013E162","journal-title":"Circulation"},{"key":"747_CR75","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1210\/jc.2002-021687","volume":"88","author":"G Van Hall","year":"2003","unstructured":"Van Hall G et al (2003) Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88:3005\u20133010","journal-title":"J Clin Endocrinol Metab"},{"key":"747_CR76","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1113\/jphysiol.2002.021022","volume":"543","author":"D Lyngs\u00f8","year":"2002","unstructured":"Lyngs\u00f8 D, Simonsen L, B\u00fclow J (2002) Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. J Physiol 543:379\u2013386","journal-title":"J Physiol"},{"key":"747_CR77","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","volume":"106","author":"N Nishimoto","year":"2005","unstructured":"Nishimoto N et al (2005) Humanized anti \u2013 interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627\u20132633","journal-title":"Blood"},{"key":"747_CR78","first-page":"0","volume":"86","author":"G P\u00e4th","year":"2007","unstructured":"P\u00e4th G et al (2007) Human breast adipocytes express interleukin-6 (IL-6) and its receptor system: increased IL-6 production by beta-adrenergic activation and effects of IL-6 on adipocyte function. J Clin Endocrinol Metab 86:0\u20137","journal-title":"J Clin Endocrinol Metab"},{"key":"747_CR79","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1210\/me.2005-0490","volume":"20","author":"L Al-Khalili","year":"2006","unstructured":"Al-Khalili L et al (2006) Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol 20:3364\u20133375","journal-title":"Mol Endocrinol"},{"key":"747_CR80","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1210\/jc.2004-0603","volume":"89","author":"ME Trujillo","year":"2004","unstructured":"Trujillo ME, Sullivan S, Harten I, Schneider SH, Greenberg AS, Fried SK (2004) Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J Clin Endocrinol Metab 89:5577\u20135582","journal-title":"J Clin Endocrinol Metab"},{"key":"747_CR81","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.2337\/db06-S007","volume":"55","author":"NB Ruderman","year":"2006","unstructured":"Ruderman NB, Keller C, Richard AM, Saha AK, Luo Z, Xiang X, Giralt M, Ritov VB, Menshikova EV, Kelley DE, Hidalgo J, Pedersen BK, Kelly M (2006) Interleukin-6 regulation of AMP-activated protein kinase: potential role in the systemic response to exercise and prevention of the metabolic syndrome. Diabetes 55:S48\u2013S54","journal-title":"Diabetes"},{"key":"747_CR82","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrm3311","volume":"13","author":"DG Hardie","year":"2017","unstructured":"Hardie DG, Ross FA, Hawley SA (2017) AMPK - a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13:251\u2013262","journal-title":"Nat Rev Mol Cell Biol"},{"key":"747_CR83","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1038\/emm.2016.81","volume":"48","author":"SM Jeon","year":"2016","unstructured":"Jeon SM (2016) Regulation and function of AMPK in physiology and diseases. Exp Mol Med 48:e245","journal-title":"Exp Mol Med"},{"key":"747_CR84","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.bbamcr.2016.01.023","volume":"1863","author":"N Longo","year":"2016","unstructured":"Longo N, Frigeni M, Pasquali M (2016) Carnitine transport and fatty acid oxidation. Biochim Biophys Acta 1863:2422\u20132435","journal-title":"Biochim Biophys Acta"},{"key":"747_CR85","doi-asserted-by":"publisher","unstructured":"Tanaka T, Hishitani Y, Ogata A (2014) Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. Biologics 8:141-53. https:\/\/doi.org\/10.2147\/BTT.S37509","DOI":"10.2147\/BTT.S37509"},{"key":"747_CR86","first-page":"349","volume":"8","author":"A Shetty","year":"2014","unstructured":"Shetty A et al (2014) Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug Des Devel Ther 8:349\u2013364","journal-title":"Drug Des Devel Ther"},{"key":"747_CR87","first-page":"269","volume":"73","author":"C Iking-Konert","year":"2014","unstructured":"Iking-Konert C et al (2014) Interleukin-6 inhibition as a potential therapeutic target in rheumatic diseases. Rheumatol. 73:269\u2013276","journal-title":"Rheumatol."},{"key":"747_CR88","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.diabres.2014.04.006","volume":"105","author":"N Esser","year":"2014","unstructured":"Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N (2014) Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 105:141\u2013150","journal-title":"Diabetes Res Clin Pract"},{"key":"747_CR89","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1517\/13543784.2015.974804","volume":"24","author":"N Esser","year":"2014","unstructured":"Esser N, Paquot N, Scheen AJ (2014) Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs 24:283\u2013307","journal-title":"Expert Opin Investig Drugs"},{"key":"747_CR90","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1136\/ard.2010.132845","volume":"70","author":"A Ogata","year":"2011","unstructured":"Ogata A, Morishima A, Hirano T, Hishitani Y, Hagihara K, Shima Y, Narazaki M, Tanaka T (2011) Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab. Ann Rheum Dis 70:1164\u20131165","journal-title":"Ann Rheum Dis"},{"key":"747_CR91","doi-asserted-by":"publisher","first-page":"e14328","DOI":"10.1371\/journal.pone.0014328","volume":"5","author":"O Schultz","year":"2010","unstructured":"Schultz O, Oberhauser F, Saech J, Rubbert-Roth A, Hahn M, Krone W, Laudes M (2010) Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (A) levels in human subjects with rheumatoid diseases. PLoS One 5:e14328","journal-title":"PLoS One"},{"key":"747_CR92","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.autrev.2017.11.030","volume":"17","author":"F Ursini","year":"2018","unstructured":"Ursini F, Russo E, Ruscitti P, Giacomelli R, De Sarro G (2018) The effect of non\u2013TNF-targeted biologics and small molecules on insulin resistance in inflammatory arthritis. Autoimmun Rev 17:399\u2013404","journal-title":"Autoimmun Rev"},{"key":"747_CR93","doi-asserted-by":"crossref","unstructured":"Casta\u00f1eda S, Remuzgo-Mart\u00ednez S, L\u00f3pez-Mej\u00edas R, Genre F, Calvo-Al\u00e9n J, Llorente I, Aurrecoechea E, Ortiz AM, Triguero A, Blanco R, Llorca J, Gonz\u00e1lez-Gay MA (2018) Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. Clin Exp Rheumatol","DOI":"10.1136\/annrheumdis-2018-eular.6998"},{"key":"747_CR94","doi-asserted-by":"publisher","first-page":"e0196368","DOI":"10.1371\/journal.pone.0196368","volume":"13","author":"Y Otsuka","year":"2018","unstructured":"Otsuka Y, Kiyohara C, Kashiwado Y, Sawabe T, Nagano S, Kimoto Y, Ayano M, Mitoma H, Akahoshi M, Arinobu Y, Niiro H, Akashi K, Horiuchi T (2018) Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study. PLoS One 13:e0196368","journal-title":"PLoS One"},{"key":"747_CR95","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1016\/j.jacc.2018.03.002","volume":"71","author":"BM Everett","year":"2018","unstructured":"Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC, Glynn RJ, Libby P, Ridker PM (2018) Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J Am Coll Cardiol 71:2392\u20132401","journal-title":"J Am Coll Cardiol"},{"key":"747_CR96","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/ard.2008.101964","volume":"68","author":"E Choy","year":"2009","unstructured":"Choy E, Sattar N (2009) Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 68:460\u2013469","journal-title":"Ann Rheum Dis"},{"key":"747_CR97","doi-asserted-by":"crossref","unstructured":"Wedell-Neergaard A-S et al (2018) Exercise-induced changes in visceral adipose tissue mass are regulated by IL-6 signaling: a randomized controlled trial. Cell Metab:1\u201312","DOI":"10.2139\/ssrn.3254906"},{"key":"747_CR98","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","volume":"371","author":"JS Smolen","year":"2008","unstructured":"Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987\u2013997","journal-title":"Lancet"},{"key":"747_CR99","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"MC Genovese","year":"2008","unstructured":"Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58:2968\u20132980","journal-title":"Arthritis Rheum"},{"key":"747_CR100","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/art.38920","volume":"67","author":"VU Rao","year":"2015","unstructured":"Rao VU, Pavlov A, Klearman M, Musselman D, Giles JT, Bathon JM, Sattar N, Lee JS (2015) An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheum 67:372\u2013380","journal-title":"Arthritis Rheum"}],"container-title":["Seminars in Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-019-00747-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00281-019-00747-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-019-00747-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T02:03:07Z","timestamp":1663466587000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00281-019-00747-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,17]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["747"],"URL":"https:\/\/doi.org\/10.1007\/s00281-019-00747-2","relation":{},"ISSN":["1863-2297","1863-2300"],"issn-type":[{"value":"1863-2297","type":"print"},{"value":"1863-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,17]]},"assertion":[{"value":"3 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}